Pricing

Foghorn Therapeutics Inc. (FHTX)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Adrian Gottschalk
Employees:
120
500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, 02139
617-586-3100
Foghorn Therapeutics Inc. is developing a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome. The company is also developing an enzyme inhibitor and protein degrader as selective modulators of BRM.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available